Researchers at Michigan Medicine have successfully reversed a severe and often intractable form of fatty liver disease in animal studies by focusing on an unexpected entry point for hepatic damage: the gastrointestinal tract.
The experimental compound, known as DT-109, tackles metabolic dysfunction-associated steatohepatitis (MASH) through a novel mechanism. Rather than focusing solely on the liver, the drug works by subduing harmful gut bacteria, fortifying the intestinal lining, and blocking inflammatory byproducts from migrating out of the digestive system and reaching the liver. These findings, recently published in The Journal of Clinical Investigation, point toward a promising new therapeutic paradigm for a condition that has historically challenged clinicians and left patients with severely limited treatment options.
MASH is a serious progression of non-alcoholic fatty liver disease that currently impacts approximately 7% of the global population. Characterized by an excessive accumulation of fat within the liver, the condition triggers chronic inflammation and progressive cellular destruction. If left unchecked, MASH can advance to cirrhosis—marked by extensive and irreversible scarring of the liver tissue—as well as primary liver cancer and eventual organ failure. While medical therapies for liver conditions have seen incremental improvements in recent years, the clinical arsenal for managing MASH remains starkly insufficient.
"We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression," said Dr. Eugene Chen, senior author of the study and the Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School. "This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH."
How Harmful Gut Bacteria Can Trigger Liver Damage
Dr. Chen’s research team had previously established that DT-109—a glycine-based tripeptide—could alleviate MASH symptoms in animal models. A tripeptide is a compact molecule constructed from three amino acids, which serve as the fundamental building blocks of proteins. However, the exact physiological pathways through which the compound exerted its protective capabilities remained a mystery until now.
This latest investigation sheds light on that biochemical chain reaction, detailing how shifts in the human microbiome can ignite a cascade of events culminating in severe liver injury, and how DT-109 effectively interrupts that destructive cycle.
Before evaluating the therapeutic impact of the drug, the scientific team verified a primary driver of MASH pathology: the overgrowth of Clostridium perfringens, a specific bacterium known for synthesizing ammonia within the human intestinal tract. When luminal ammonia concentrations rise abnormally, they begin to compromise the delicate inner lining of the gut. Under healthy physiological conditions, this intestinal epithelial barrier acts as a selective filter, preventing potentially noxious agents residing in the digestive tract from leaking into the systemic circulation.
As this protective barrier deteriorates, however, metabolic toxins and microbial byproducts escape the gut and travel directly to the liver via the portal vein. Upon arrival, these foreign substances provoke localized inflammation and trigger aggressive immune responses that accelerate tissue damage.
One critical component of this inflammatory cascade involves the hyperactivation of CD8+ T cells. While these specialized immune cells normally protect the body by destroying virus-infected or malignant cells, their chronic overstimulation in the context of a compromised gut-liver axis heavily fuels the inflammatory pathology characteristic of MASH. These insights help clarify why a debilitating disease centered fundamentally in the liver is so profoundly influenced by biological processes occurring downstream in the digestive tract.
Experimental Drug Repairs the Gut and Protects the Liver
Through a comprehensive sequence of laboratory trials, the Michigan Medicine researchers discovered that DT-109 disrupts this vicious cycle by rehabilitating the intestinal environment and reinforcing the structural integrity of the gut barrier.
Testing the compound across both murine models and nonhuman primates, the team observed that DT-109 successfully suppressed populations of Clostridium perfringens and lowered luminal ammonia production. These localized improvements within the intestines directly enhanced the resilience of the gut lining, successfully restricting the translocation of harmful microbial agents into the wider body and shielding the liver from secondary injury.
The therapeutic outcomes were particularly compelling in nonhuman primate trials. Because the digestive physiology and gut microbiome compositions of nonhuman primates mirror human biology much more closely than those of mice, these results carry significant translational weight. In these primate models, administration of DT-109 visibly diminished hepatic inflammation and reduced the overall clinical severity of MASH.
Taken together, these results underscore how therapeutic interventions directed at the gastrointestinal tract can yield profound systemic benefits for the liver, operating primarily outside the organ itself.
"DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis," said Dr. Jifeng Zhang, co-author and research professor of cardiovascular medicine at the U-M Medical School. "We also found that DT-109 primarily acts in the gastrointestinal tract, but its reach stretches much further."
This interconnected biological relationship between the digestive system and the liver is formally known as the gut-liver axis. Because venous blood from the intestines flows straight to the liver, hepatic health is intimately tied to the shifting composition of gut bacteria and the physical competence of the intestinal barrier. By intervening directly at this junction, DT-109 provides a way to target the root drivers of liver inflammation rather than simply managing downstream tissue damage after it has occurred.
Potential Benefits Beyond Fatty Liver Disease
Given its capacity to preserve intestinal barrier function, investigators theorize that DT-109 could hold therapeutic value for a wider spectrum of inflammatory and metabolic conditions.
Previous studies from the same research group demonstrated that DT-109 can suppress the formation of atherosclerotic plaques and mitigate vascular calcification in nonhuman primates. Atherosclerosis involves the accumulation of cholesterol, fats, and inflammatory cells within arterial walls, which restricts blood flow and significantly elevates the risk of heart attacks and strokes. Vascular calcification, meanwhile, describes the pathological hardening of blood vessels caused by calcium deposits, further compromising cardiovascular health.
The convergence of these findings suggests that DT-109 could eventually be deployed to manage both hepatic and cardiovascular diseases concurrently—a major clinical advantage given that metabolic disorders frequently affect multiple organ systems at once.
Furthermore, the research team is actively exploring whether the compound might offer relief for individuals suffering from inflammatory bowel disease (IBD), a category of chronic gastrointestinal disorders that includes Crohn’s disease and ulcerative colitis. Because compromised intestinal barrier integrity is a hallmark of numerous gut-related ailments, a pharmacological agent capable of reinforcing this barrier could theoretically extend its clinical utility far beyond hepatology. However, extensive dedicated research will be required to confirm whether DT-109 can safely and effectively treat these separate gastrointestinal pathologies.
A Promising Treatment That Still Needs Human Trials
Despite these encouraging preclinical results, DT-109 remains an experimental pharmaceutical agent. While its ability to reverse MASH has been robustly demonstrated in animal models, researchers have yet to establish whether the compound can achieve a similar safety and efficacy profile in human patients.
The next critical phase of investigation will involve rigorous pharmacological evaluations aimed at moving the compound into clinical trials. These upcoming human studies will be indispensable for determining proper dosing schedules, verifying long-term safety, and measuring clinical effectiveness in patients struggling with advanced metabolic liver disease.
"This study presents novel evidence about the pathogenesis of MASH and provides excitement about a therapeutic avenue to explore for a condition that remains difficult to treat," said Dr. Elliot Tapper, Academic Director of Hepatology at Michigan Medicine. "What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health—of course we are excited about these developments."
This breakthrough reflects a broader conceptual evolution in modern medicine regarding how researchers approach fatty liver disease. By shifting focus toward the gut microbiome and the mechanical strength of the intestinal barrier, science may soon deliver liver-protective therapies that operate primarily beyond the boundaries of the liver itself. If upcoming human clinical trials successfully replicate the safety and efficacy observed in animal models, DT-109 could establish an entirely new class of therapeutics for severe fatty liver disease while simultaneously protecting against dangerous cardiovascular complications.
Funding for the research and related intellectual property developments involves several disclosed interests. Ying Zhao, Oren Rom, Jifeng Zhang, and Dr. Y. Eugene Chen are named as inventors on a pending patent application covering tripeptides and their use in treating metabolic, cardiovascular, and inflammatory disorders. Dr. Chen is also recognized as an inventor specifically for DT-109. The University of Michigan holds the underlying patent for the compound and has licensed commercial development rights to Diapin Therapeutics. Both Dr. Chen and the university maintain financial ownership interests in Diapin, which provided the DT-109 supply utilized in these studies.
Clinical protocols and animal research procedures adhered strictly to institutional and international ethical standards. Human protocol approvals were secured from the Institutional Review Boards at participating international medical centers, including the First Affiliated Hospital of Xi’an Jiaotong University, the Institutional Review Board of Jinan University, and the University of Hong Kong/Hospital Authority Hong Kong West Cluster. Animal research protocols involving nonhuman primates were authorized by the Laboratory Animal Care Committee of Xi’an Jiaotong University and the Institutional Animal Care and Use Committee of Spring Biological Technology Development Co., Ltd., in full compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.